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psb.2020.10.002Abstract Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be
effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to
LHQW components and their pharmacological effects remain largely unknown. Hence, this study aimed
to determine human exposure to LHQW components and their anti-COVID-19 pharmacological activ-
ities. Analysis of LHQW component profiles in human plasma and urine after repeated therapeutic dosing
was conducted using a combination of HRMS and an untargeted data-mining approach, leading to detec-
tion of 132 LHQW prototype and metabolite components, which were absorbed via the gastrointestinal
tract and formed via biotransformation in human, respectively. Together with data from screening by
comprehensive 2D angiotensin-converting enzyme 2 (ACE2) biochromatography, 8 components in
LHQW that were exposed to human and had potential ACE2 targeting ability were identified for further
pharmacodynamic evaluation. Results show that rhein, forsythoside A, forsythoside I, neochlorogenic
acid and its isomers exhibited high inhibitory effect on ACE2. For the first time, this study provides
chemical and biochemical evidence for exploring molecular mechanisms of therapeutic effects of LHQW
capsule for the treatment of COVID-19 patients based on the components exposed to human. It also dem-
onstrates the utility of the human exposure-based approach to identify pharmaceutically active compo-
nents in Chinese herb medicines.
ª 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recently, a new type of coronavirus disease 2019 (COVID-19),
with rapid spread and high morbidity, broke out worldwide.
Fortunately, a number of endeavors revealed that traditional Chi-
nese medicine (TCM) treatment could effectively relieve symp-
toms and prevent the fatal deterioration of this disease1e4. As a
typical TCM formulation, Lianhuaqingwen (LHQW) capsule has
been confirmed to show therapeutic effects by clinical research
and observation5,6. More importantly, in April 2020, the “Phar-
maceutical Supplement Application Document” issued by Na-
tional Medical Products Administration (NMPA) showed that
LHQW (granules formulation) were approved to treat fever,
cough, or fatigue caused by the mild or common types of COVID-
19. In details, the course of treatment is from 7 to 10 days, indi-
cating the effectiveness of LHQW in treating COVID-19. How-
ever, the pharmaceutical components and pharmacological
mechanism of LHQW in fighting COVID-19 are still largely
unexplored.
LHQW is a patented Chinese medicine product developed for
the treatment of cold and influenza7,8 and it was approved for
marketing by the NMPA in 2004. LHQW has the functions of
clearing away heat and detoxifying the lungs, and thus it is also
clinically used to treat patients with the symptoms of fever and
stagnation of the lung9. An anti-influenza A (H1N1) trial
demonstrated that LHQW had better effect on the alleviation of
fever, cough, sore throat, and fatigue, in comparison with oselta-
mivir. Furthermore, it showed comparative therapeutic effective-
ness in reduction of illness duration and viral shedding
duration8,10. Although molecular targets of LHQW remain un-
known, pharmacological activities of LHQW have been explored
in vitro. Ding et al.7 reported that the raw material of LHQW
(dissolved in DMSO as stock solution) inhibited the proliferation
of influenza viruses from various strains in vitro, with the 50%
inhibitory concentration (IC50) ranging from 0.35 to 2 mg/mL.
And it could also suppress virus-induced nuclear factor kB
(NF-kB) activation and alleviate virus-induced gene expression of
interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-ai et al., Identifying potential anti-C
an exposure and ACE2 biochromato(TNF-a), interferon-g-inducible protein-10 (IP-10), and monocyte
chemoattractant protein-1 (MCP-1). Using a similar in vitro
approach, it was demonstrated that LHQW exerted anti-SARS-
CoV-2 activity via inhibiting virus replication and reducing
cytokine release from host cells5. Furthermore, networking anal-
ysis has been applied to identify main effective components in raw
LHQW materials. For example, Wang et al.11 revealed 15 active
components of LHQW and 61 related targets by using network
pharmacology. Furthermore, You et al.12 found that the active
components of LHQW might inhibit cytokine storm by regulating
various inflammatory signal pathways by network pharmacology
analysis. Just like a Western medicine product, it is well recog-
nized that the efficacy and safety of TCM are associated with the
chemical constituents of TCM including prototype components
and their metabolites in the circulation, which are directly asso-
ciated with the whole process of absorption, distribution, meta-
bolism, and excretion (ADME)13,14. Identification of TCM
components in animals or human circulation followed by activity
testing of these components is another approach to study molec-
ular mechanisms of pharmacological effects of TCM. For
example, Wang et al.15 combined serum pharmacochemistry-
based screening and high-resolution metabolomics analysis to
find bioactive components. However, information on exposure,
metabolism and disposition of LHQW in animals or human is not
available in the literatures.
In addition to directly testing extracted raw materials from a
TCM product or virtual network pharmacology analysis, phyto-
chemical separation of individual components followed by phar-
macological activity testing in vitro is a more common and useful
practice in searching for active constitutes of an effective herbal
medicine product16. However, this approach may not be able to
focus on TCM components that are either absorbed in and exposed
to human after oral administration or formed in human via
biotransformation by metabolizing enzymes in human.
The first primary objective of this study was to determine the
component profiles of LHQW in human plasma and urine, after
oral administration of multiple therapeutic doses to human sub-
jects. The LHQW formula was composed by 13 herb components:OVID-19 pharmacological components of traditional Chinese medicine
graphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
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+ MODELlianqiaodForsythiae Fructus; jinyinhuadLonicerae Japonicae
Flos; zhimahuangdEphedrae Herba Praeparata Cum Melle;
chaokuxingrendArmeniacae Semen Amarum Tostum; shi-
gaodGypsum Fibrosum; banlangendIsatidis Radix; mianma-
guanzhongdDryopteridis Crassirhizomatis Rhizoma;
yuxingcaodHouttuyniae Herba; guanghuoxiangdPogostemonis
Herba; dahuangdRhei Radix et Rhizoma; hongjingtiandRho-
diolae Crenulatae Radix et Rhizoma; bohenaodL-menthol; and
gancaodGlycyrrhizae Radix et Rhizoma. Analysis of major
constitutes in LHQW was conducted by using liquid chromatog-
raphy coupled with high-resolution mass spectrometry
(LCeHRMS), leading to unambiguous confirmation or tentative
identification of 61 compounds, including flavonoids, phenyl-
propanoids, anthraquinones, triterpenoids, iridoids, and other
types of compounds. Among these compounds, salidroside,
chlorogenic acid, forsythoside E, cryptochlorogenic acid, amyg-
dalin, sweroside, hyperin, rutin, forsythoside A, phillyrin (for-
sythin), rhein, and glycyrrhizic acid (glycyrrhizin) are considered
chemical markers17. Detection and structural characterization of
TCM components in complex biological matrix represent great
analytical challenges, which are heavily dependent on LCeHRMS
instrumentation and data-mining technologies. Although targeted
data mining tools, such as extracted ion chromatography, product
ion filter and mass defect filters, are routinely employed in find
TCM metabolites in vivo18, metabolomics approach has been
increasingly used for untargeted detection of TCM components14.
In this study, we applied a previously developed analytical strat-
egy for studying ADME of TCM in vivo19,20, which used precise-
and-thorough background subtraction (PATBS) for sensitive and
comprehensive detection and structural characterization of TCM
components in complex biological samples.
The second primary objective of this study was to identify
potential anti-COVID-19 pharmacological components of LHQW,
that were exposure to human after multiple oral doses. SARS-
CoV-2 was reported to achieve human infections through the
binding of its spike protein (S protein) to angiotensin converting
enzyme 2 (ACE2) as receptor21, which is a negative regulator with
the ability to maintain the steady state of renin-angiotensin system
(RAS) and is critical to the physiology or pathology of all or-
gans22. ACE2 has been found to be widely distributed in the heart,
kidney, testis, adipose tissue, brain tissue, vascular smooth muscle
cells, and gastrointestinal tract23. Zhao et al.24 applied high-
throughput single-cell sequencing analysis technique to study
43,134 lung cells and found that ACE2 was expressed in 0.64%
lung cells, and in 1.4% alveolar type II cells (AT2), which became
the binding targets of SARS-CoV-2 as an invasion starting point.
Furthermore, Xu et al.25 confirmed that ACE2 is a viral receptor
by studying the binding capacity of the SARS-CoV-2 protein
crystal structure to human ACE2 receptor. In general, the above
studies indicated that screening drugs with ACE2 targeting ability
are promising for the treatment of patients with SARS-CoV-2
infection. Hence, comprehensive 2D ACE2 biochromatography
system was established for efficiently screening for active LHQW
components exposed to human after repeated oral does. The ACE2
inhibitory activity of hits from the biochromatography screening
was further confirmed by using the pharmacodynamics study of
surface plasmon resonance (SPR) and analysis using ACE2
inhibitory activity assay kit as well as supported by results from
docking simulation.Please cite this article as: Chen Xiaofei et al., Identifying potential anti-C
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j.apsb.2020.10.0022. Methods and materials2.1. Chemicals and materials
Methanol (batch No.: 19105007) and acetonitrile (batch No.:
10105007) were purchased from TEDIA (Fairfield, OH, USA).
Formic acid (batch No.: 73C1707EN) was purchased from Ana-
qua Chemical Supply (Wilmington, DE, USA). Ultra-pure water
was prepared by Milli-Q water purification system (Bedford, MA,
USA). Oasis HLB 3cc (60 mg) extraction cartridges (batch No.:
164A39127A) was from Waters (Milford, MA, USA). Silica gel
(5 mmol/L, 200 Å) was purchased from Qingdao Meigao Chem-
ical Co., Ltd. (Qingdao, China). N,N-Dimethylformamide (DMF),
mercaptopropyltrimethoxysilane (MPTS), N-(4-maleimide butyryl
oxide)succinimide (GMBS) and dimethyl sulfoxide (DMSO) were
purchased from Sigma (St. Louis, MO, USA). ACE2 recombinant
protein (human, His tag, Cat: 10108-H08H) was obtained from
Sino Biological Co. (Beijing, China). ACE2 primary antibody
(rabbit IgG) was purchased from Abmart Biological Co.
(Shanghai, China). MLN-4760 (CAS#305335-31-3) was pur-
chased from MedChemExpress (Monmouth Junction, NJ, USA).
TCM reference substances, ephedrine and pseudoephedrine, were
supplied by National Institutes for Food and Drug Control (Bei-
jing, China); (R,S)-goitrin, salidroside, forsythoside E, amygdalin,
secoxyloganin, liquiritin, forsythoside I, luteolin-7-O-glucoside,
forsythoside B, forsythoside H, forsythoside A, isoquercitrin,
kaempferol-3-O-neohesperidoside, quercitrin, forsythin, quer-
cetin, phillygenin, aloe-emodin, glycyrrhizin, rhein, emodin,
chrysophanol and physcion were supplied by Baoji Chenguang
Biotechnology Co., Ltd. (Baoji, China); prunasin was supplied by
BioBioPha (Yunnan, China); gallic acid, neochlorogenic acid,
chlorogenic acid, cryptochlorogenic acid, rutin, kaempferol-3-O-
rutinoside, emodin 8-O-b-D-glucoside, kaempferol were supplied
by Chengdu Purechem-Standard Company (Chengdu, China).2.2. Collection of clinical samples
A single-center, randomized, open, and multiple-dose trial was
designed to enroll 14 healthy subjects. Each subject was
confirmed (by physical examination, laboratory examination, or
electrocardiogram) to have no heart, liver and kidney diseases; no
history of allergies, and no LHQW or other drug or food admin-
istration, which might affect drug absorption, distribution, meta-
bolism, and excretion within one month before the test. This study
protocols were approved by the Ethics Committee of Hebei Yiling
Hospital (Shijiazhuang, China), and all subjects signed a written
informed consent before entering this study (the clinical trial
registration number: 2019LS-002). This test was conducted by
continuous administration (the dose was 4.2 g, 12 capsules), which
was given on Days 1e8, except Day 2. Furthermore, the sampling
(blood and urine) was taken on Days 1 and 2 after administration,
while the blood samples were collected on Days 3e7 before each
administration as well as on Day 8 (blood and urine). And the
overall test period was 11 days. The subjects were requested to
have their breakfast 1 h before drug administration, and to finish
within 30 min before drug administration with 240 mL warm
water. And the collected plasma and urine samples were stored in
80 C refrigerator before testing.OVID-19 pharmacological components of traditional Chinese medicine
raphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
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10 mg powder of LHQW capsule was dissolved in 2 mL 70%
methanol, diluted one time and filtered by 0.22 mm filter mem-
brane to obtain a final LHQW test solution of 2.5 mg/mL.
The plasma samples from 6 subjects (subject numbers 1, 3, 6,
8, 9, and 12) on Day 8 were prepared as follows. The plasma
samples from subjects taken at 10, 30 min, 1, 3, 6, 9, 12, 16, 25, or
48 h after drug dosing (50 mL plasma at each time point) were
mixed to obtain a 3-mL sample. After dilution for 3 times with
ultrapure water, the samples were respectively enriched and pu-
rified by Oasis HLB 3cc (60 mg) extraction cartridges. The
methanol eluent was collected and dried with nitrogen. Re-
constitutes were obtained by re-dissolving the residues using
100 mL 70% methanol. After 10 s of ultrasonication, vortex
mixing, and 12,000 rpm centrifugation (D3024, DLAB Scientific
Co., Beijing, China) for 5 min, the supernatants were collected for
further analysis. Before administration, blank plasma samples
were prepared in a similar manner.
The urine samples from 6 subjects (subject numbers 1, 3, 6, 8,
9, and 12) on Day 8 were prepared as follows. The urine samples
from subjects collected in the periods of 0e4, 4e10, 10e24,
24e32, or 32e48 h after drug dosing (100 mL urine at each time
point) were mixed to obtain a 3-mL sample. Furthermore, the
samples were respectively enriched and purified by Oasis HLB
3cc (60 mg) extraction cartridges. The methanol eluent was
collected and dried with nitrogen at 37 C. Reconstitutes were
obtained by re-dissolving the residues using 100 mL 70% meth-
anol. After 10 s of ultrasonication, vortex mixing, and 12,000 rpm
centrifugation (D3024, DLAB Scientific Co., Beijing, China) for
5 min, the supernatants were collected for further analysis. Before
administration, blank urine samples were prepared in a similar
manner.
2.4. UPLCeHRMS analysis
To determine component profiles of LHQW in human body,
human plasma and urine samples were detected with Thermo
Fisher Q Exactive Orbitrap LCeMS/MS equipped with electro-
spray ionization (ESI, Thermo Fisher Scientific, Waltham, MA,
USA) in positive and negative ion modes which was controlled by
Thermo Xcalibur 3.0.63 (Thermo Fisher Scientific). An ACQ-
UITY UPLC CSH C18 column (50 mm  2.1 mm, 1.7 mm) was
used to separate the sample with the temperature set at 35 C.
Mobile phase A was H2O with 0.1% formic acid, and mobile
phase B was 100% acetonitrile with a flow rate of 0.3 mL/min.
The gradient was set as follows: 0e3 min (2% B); 3e4 min (2%e
5% B); 4e6 min (5% B); 6e9 min (5%e10% B); 9e14 min
(10%e15% B); 14e18 min (15%e20% B); 18e25 min (20%e
30% B); 25e28 min (30%e95% B); 28e32 min (95% B);
32.01e37 min (5% B). The injection volume was set as 3 mL, and
the eluent was monitored at l 205, 254 and 310 nm.
In order to optimize the mass spectrometry conditions, 8
reference materials with different structures were selected
(ephedrine and (R,S)-goitrin were chosen in positive ion mode;
while forsythoside A, forsythin, rhein, glycyrrhizin, amygdalin,
and luteolin-7-O-glucoside were chosen in negative ion mode).
These references at the concentration of 10 mg/mL and velocity of
3 mL/min were utilized to optimize the MS conditions. The op-
timizations included the proper ionization mode (positive ion
mode/negative ion mode), spray voltage, capillary temperature,Please cite this article as: Chen Xiaofei et al., Identifying potential anti-C
Lianhuaqingwen capsule based on human exposure and ACE2 biochromato
j.apsb.2020.10.002capillary voltage, RF lens, auxiliary gas, and sweep gas flow rate.
Full MS and data dependent tandem mass spectrometry 2 (ddMS2)
in both positive and negative ion mode were used to acquire full
scan MS and MS data of LHQW raw materials, plasma and urine
samples. The scan mass range 100e1200 Da was selected. High
resolution full-scan MS and MS2 data were collected at resolving
power of 35,000 and 17,500, respectively. Stepped HCD collision
energy of 35% was used. The temperature of capillary was set at
320 C, and the spray voltage was 3.5 kV for negative ion mode,
and 3.8 kV for positive ion mode. The flow rate of sheath gas (N2)
and auxiliary gas (N2) were 40 and 10 arb, respectively. The data
obtained were analyzed by Thermo Xcalibur 3.0.63 Qual Browser
(Thermo Fisher Scientific).
After collection of MS and MS/MS data of the LHQW test
solution, structural characterization and confirmation of LHQW
constituents were carried out by using Compound Discoverer 3.1
software (Thermo Fisher Scientific). The main parameters of this
software were set as follows: align retention times, maximum shift
2 min; mass tolerance, 5 ppm; detect compound, mass tolerance
5 ppm; intensity tolerance, 30%; minimal peak intensity, 500,000;
data sources, mzCloud, mzVault, MassList, and ChemSpider
Search; and S/N threshold, 3, after which the compounds search-
ing and matching were conducted. And then, the software
searching report was combined with the fragmentation rule of
reference MS as well as the corresponding characteristic fragment
ion information. In addition, 34 reference standards were used for
structural confirmation.
Detection and structural characterization of LHQW compo-
nents in human plasma and urine were carried out by a
LCeHRMS workflow, which was previously developed for
ADME study of a TCM product in vivo19. Briefly, the workflow
used PATBS, an untargeted data-mining technology, to detect
LHQW components in a plasma or urine sample. Once the LHQW
components were found in full scan LCeHRMS dataset, their
MS/MS spectral data were either retrieved from the MS/MS
datasets acquired by ddMS2 methods or acquired via targeted
production ion scanning analysis. And then, structural conforma-
tion of prototype components of LHQW in the plasma and urine
samples was accomplished by comparing their LCeHRMS data
with LHQW test solution. Meanwhile, metabolites of LHQW
components were structurally characterized using some functions
of Compound Discoverer 3.1 software, including biotransforma-
tion matching, spectral similarity comparison and fragmentation
interpretation.2.5. Synthesis of ACE2 biochromatographic stationary phase
The reaction scheme was shown in Fig. 1A, according to the
method developed in our previous research with slight modifica-
tion26. Briefly, 1 mL MPTS was added to 1 g silica gel and stirred
for 5 h in 100 mL DMF under the condition of 60 C and nitrogen
protection. The suspension was cleaned with DMF at 5000g for
three times. Then the precipitate was obtained and reacted with
5% GMBS in 500 mL DMSO solution for 2 h. The MPTS/GMBS
modified silica gel was cleaned with DMSO at 5000g for three
times and dried in the vacuum drying pump for 48 h before use.
ACE2 recombinant protein (20 mg) was mixed with MPTS/
GMBS-modified silica gel (40 mg) in PBS for continuous stir-
ring for 12 h at 4 C, realizing the covalent immobilization of
ACE2 protein on silica stationary phase.OVID-19 pharmacological components of traditional Chinese medicine
graphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
Figure 1 (A) Synthetic route of MPTS/GMBS-modified silica gel and ACE2 biochromatographic stationary phase; (B) ACE2 bio-
chromatographic stationary phase was digested by 0.3% pronase and lysed by RIPA buffer, then immunoblotted with the anti-ACE2 antibody.
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column/time-of-flight mass spectrometry (TOFMS) system
The comprehensive 2D ACE2 column/C18 column/TOFMS sys-
tem was performed on an Agilent 1200 series HPLC system
coupled with a 6220 TOF mass spectrometry consisting of an
auto-sampler, which was controlled by Agilent MassHunter
Workstation (Agilent Technologies, Palo Alto, CA, USA). As
shown in Supporting Information Fig. S1, the ACE2 column
(10 mm  2.0 mm i.d., 5 mm) was equipped as the first dimen-
sional column with 10 mmol/L ammonia acetate as the mobile
phase, and the flow rate set at 0.2 mL/min. For the second
dimension, an Agilent Poroshell 120 EC-C18 column
(150 mm  3.0 mm i.d., 2.7 mm) was applied with the mobile
phase composed of solvent A (0.1% formic acid) and solvent B
(acetonitrile) at 0.4 mL/min. The linear gradient elution program
is: 0e12 min, 5%e20% B; 12.01e17 min, 20%e70% B;
17.01e20 min, 5% B. Other detailed parameters, modules and
operations of the comprehensive 2D system were described in our
previous studies27,28.
2.7. SPR analysis
SPR assays were performed on Biacore T200 system (GE
Healthcare Life Sciences, Marlborough, MA, USA). ACE2 re-
combinant protein with HIS label was diluted with acetate
(pH Z 4.0) and conjugated to a Series S Sensor Chip CM5
(BR100530, GE Healthcare Life Sciences) by EDC/NHS cross-
linking reaction according to manufacturer’s protocols. The target
immobilization level of ACE2 protein was 8000 RU. Small mol-
ecules were diluted with a running buffer containing 5% DMSO
from 0.024 to 50 mmol/L, and was injected into the reference
channel and ACE2 protein channel, respectively, at a flow rate of
30 mL/min. The coupling and dissociation time were both 120 s.
Biacore T200 evaluation software was used to fit the affinity
curves by the steady-state affinity model (1:1), and the equilibrium
dissociation constant (KD) was calculated.
2.8. Test of ACE2 inhibitory activity
The ACE2 inhibitory activities of the candidate active components
were tested by ACE2 Inhibitor Screening Kit (Catalog #K310;Please cite this article as: Chen Xiaofei et al., Identifying potential anti-C
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manufacturer’s written instructions. All data points were tested
with one duplication and were expressed by mean values. The IC50
was calculated by the nonlinear fit tool of GraphPad Prism
7.00.2.9 (La Jolla, CA, USA).
2.9. Molecular docking assay
X-ray crystal structure of protein ACE2 was downloaded from the
Protein Data Bank (PDB code: 6M0J) database. Glide in Schrö-
dinger v2019.03 (Schrödinger Inc., Plainview, NY, USA) was used
for molecular docking simulations of ligandeprotein interactions
and predicting the binding affinity and sites with ACE2. The 2D
structures of the molecules were chemically standardized
(including adding hydrogen atoms, ionizing at the pH range from
5.1 to 9.1, and generating stereoisomers and valid single 3D
conformers) by means of the LigPrep module in Maestro. The
structure of ACE2 was manipulated with the “Protein Preparation
Wizard” workflow in Maestro. The main manipulations are
removing all water molecules, protonation, and optimization
based on OPLS_2005 force field. The Glide module is used to
generate a protein receptor’s grid file to determine the active site
of the protein in order to mimic the binding of ligands and pro-
teins. The grid encloses a box centered on the binding sites of
SARS-CoV-2 S protein or active sites of ACE2 peptidase with a
dimension of 101010 (xyz, Å). The scaling factor of 0.8
was set for van der Waals radii of receptor atoms with a partial
atomic charge less than 0.15. Extra precision of Glide docking
procedure (Glide-XP) was employed for docking the compounds
to the binding site of protein and the best docking pose of the
compound was kept based upon Glide scoring function (G-score).
3. Results
3.1. UPLCeHRMS analysis of chemical constituents of LHQW
To facilitate the identification of LHQW components in human
plasma and urine, LHQW test solution was first analyzed by the
UHPLCeHRMS. As shown in Fig. 2, a total of 185 significant
constituents were found in the LHQW test solution. Their accurate
MS and MS/MS data were summarized in Supporting Information
Table S1. Based on spectral interpretation and database search,OVID-19 pharmacological components of traditional Chinese medicine
raphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
Figure 2 Analysis of LHQW components in the test solution by UPLC-UVeHRMS. (A) UPLCeUV chromatogram (254 nm); (B) Negative
ion mode high resolution total ion current chromatogram; (C) Positive ion mode high resolution total ion current chromatogram. The peaks with
red labels show that the constituents have been confirmed in comparison with the references.
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constituents have been confirmed in comparison with the refer-
ences (Supporting Information Fig. S2).
3.2. Detection and characterization of LHQW components in
human plasma and urine
An unprocessed chromatographic profile of a human urine
sample after LHQW administration (Fig. 3B) shows that a ma-
jority of peaks were endogenous components as those in a
control urine sample (Fig. 3A) although several LHQW com-
ponents were detected. In contrast, a PATBS-processed chro-
matographic profile of the same urine sample was able to reveal
about 106 LHQW-related components (Fig. 3D and E). In
addition, PATBS processing significantly improved quality of
full-scan MS dataset. For an example, full-scan MS spectrum of
a LHQW component (Rhein-GluA) shows a single molecular
ion of Rhein-GluA without any significant interference ion
species (Fig. 3C and F). Consequently, accurate MS/MS spectral
data of the detected LHQW components in the urine sample
were retrieved from recorded MS/MS datasets or acquired by
additional injections. Structural characterization of the LHQW-
related components were further accomplished by comparingPlease cite this article as: Chen Xiaofei et al., Identifying potential anti-C
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(Fig. 2), reference standards, as well as spectral interpterion and
biotransformation marching. As a result, 70 LHQW components
in the human urine were tentatively identified or confirmed
(Table S1).
Fig. 4A and B are representatively extracted ion chromato-
grams of LHQW components in negative ion and positive ion
modes, respectively, in a human plasma sample after oral
administration of repeated doses. A total of 107 LHQW com-
pounds were found in human plasma, including 66 prototype
components and 41 metabolite components, among which 72
components were structurally characterized (Table S1). In addi-
tion to detection and structural characterization, the
UPLCeHRMS profiles provides semi-quantitative information on
the LHQW components, while LCeUV profile of the plasma does
not exhibit a majority of these LHQW components due to low
concentration in human plasma. Based on the results of analyzing
urine (Supporting Information Fig. S3) and plasma samples, 87
significant LHQW prototype components were absorbed after
repeated oral administration, and 45 LHQW metabolite compo-
nents were formed in humans (Table S1). Thus, we considered that
a total of 132 LHQW related components were exposed to human
after repeated oral administration of LHQW.OVID-19 pharmacological components of traditional Chinese medicine
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+ MODEL3.3. Synthesis and characterization of ACE2
biochromatographic stationary phase
MPTS and GMBS were applied for biochromatographic sta-
tionary phase modification, in order to achieve covalent
immobilization of ACE2 recombinant protein for screening
potential anti-COVID-19 components from LHQW. Using this
strategy, the interaction yield of mercapto with the maleamide
group was high under mild reaction conditions and the self-
polymerization could be avoided26. The exposed N-hydrox-
ysuccinimide groups were practical linkages for amine coupling
of target proteins with high recovery and stable chemical
environment29. As shown in Fig. 1B, ACE2 antibody-based
immunoblotting shows that the immobilized ACE2 could be
digested by 0.3% pronase from the ACE2 biochromatographic
stationary phase, indicating the successful covalent immobili-
zation of ACE2. The content of immobilized membrane protein
on 40 mg MPTS/GMBS modified silica gel was measured as
18.24  1.05 mg, while a good protein recovery of >90% was
achieved.Figure 3 Analysis of LHQW components in a human urine sample using
Chromatography profile of full scan MS analysis a blank urine sample (pred
human urine sample. (C) Full scan MS spectrum of a LHQW component (R
the urine sample. (D) PATBS-processed chromatography profile from full sc
(D). (F) Full scan MS spectrum of the LHQW component [RheinþGluA
Green triangle indicates LHQW prototype or metabolite components in u
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column/TOFMS system
As shown in Fig. S1A, the first fraction from the ACE2 bio-
chromatography column was enriched into a 500 mL sample loop
1 at the 10-port valve switched at position 1. After switching to
position 2 (Fig. S1B), the enriched components in sample loop 1
were pumped into an Agilent Poroshell EC-C18 column and
TOFMS detector, for further separation and qualitative analysis of
chemical components. Meanwhile, the second fraction of ACE2
column was pumped into sample loop 2 and waited for analysis,
with the alternate switching of 10-port valve. In order to get
comprehensive 2D biochromatographic analysis results, it was
necessary to collect at least two fractions across a retention peak.
Hence, the collection period was set at 2.5 min for each round of
analysis. This novel comprehensive 2D ACE2 column/C18 col-
umn/TOFMS system realizes the automated and high-throughput
analytical process, rapid separation, and accurate identification,
which are helpful in discovering potential ACE2 target ligands
from complex chemical samples.UPLCeHRMS (negative ion mode) and PATBS data-processing. (A)
osed sample). (B) Chromatography profile of full scan MS analysis the
heinþGluA (164)) at 21.12 min from unprocessed LCeMS dataset of
an MS analysis of the urine sample. (E) The partially enlarged view of
(164)] from PATBS-processed LCeMS dataset of the urine sample.
rine, while the red triangle indicates the endogenous constituents.
OVID-19 pharmacological components of traditional Chinese medicine
raphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
8 Xiaofei Chen et al.
+ MODEL3.5. Screening of ACE2 binding components from enriched
urine sample and extract of LHQW
The comprehensive 2D ACE2 column/C18 column/TOFMS sys-
tem was applied into screening potential ACE2 target components
from enriched urine sample and extract of LHQW. As shown in
Fig. 5A, MLN-4760, a selective ACE2 inhibitor, had significant
retention on ACE2 biochromatography, indicating the specificity
of this screening model. Furthermore, urine samples of LHQW
were combined and enriched for biochromatographic analysis.
Interestingly, 7 significant retention components were screened
out after deducting the blank urine background (Fig. 5B). More
importantly, the complex components from the extract could also
be characterized by the 2D spectrum, obtained from the compre-
hensive 2D ACE2 biochromatography system (Fig. 5C). In details,
these prototype components and their metabolites were tentatively
identified by TOFMS according to the “generate formula from
mass peak” function of Agilent MassHunter Qualitative Analysis
software and the data of fragment ions. As shown in Supporting
Information Table S2, 10 candidate active components (8 proto-
type components and 2 metabolites) with retention behaviors from
1st dimensional ACE2 biochromatography column were listed.
Furthermore, as shown in Fig. 5D, 8 prototype components and
prunasin (metabolite of amygdalin) were validated by authentic
standard compounds in this model, which had similar retention
behaviors with that in urine sample and LHQW extract, indicating
these components could have binding affinity to ACE2 protein.
Experimental results reveal that the comprehensive 2D ACE2
bichromatography system is a practical approach for rapid
recognizing ACE2 target components from complex TCM extract.
It could also be applied to other TCM formulas or chemical li-
braries for discovering anti-SARS-CoV-2 virus candidate drugs.
However, this method is a preliminary screening tool for complex
chemical sample, which could not obtain the definite interaction
parameters between ligand and protein. Thus, the detailed pa-
rameters of the interactions between candidate components with
ACE2 required further validation.Figure 4 High-resolution extracted ion chromatograms of LHQW co
analysis in negative ion mode. (B) Data from UPLCeHRMS analysis in
ents have been confirmed in comparison with the references.
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screening of ACE2 bichromatography, 8 candidate active com-
ponents with potential ACE2 binding activity were obtained,
including neochlorogenic acid and its isomers (19), amygdalin
(33), prunasin (37), forsythoside I (104), rutin (124), forsythoside
A (128), glycyrrhizin (222) and rhein (226).
3.6. SPR analysis of candidate constituents
SPR affinity assays were performed to validate the affinities of 8
candidate active components to ACE2 recombinant protein. As
shown in Fig. 6A, MLN-4760 showed a strong affinity to ACE2
recombinant protein on SPR chips with 0.029 mmol/L, indicating
the SPR analytical system has good selectivity for screening po-
tential ACE2 inhibitors. The sensorgrams and KD fitting curves of
neochlorogenic acid (19), amygdalin (33), prunasin (37), for-
sythoside I (104), rutin (124), forsythoside A (128), glycyrrhizin
(222) and rhein (226) are shown in Fig. 6BeI, respectively. The
detailed SPR assay results of candidate active components were
listed in Table 1. We found that amygdalin and prunasin had
strong binding affinities of KD Z 0.221 and 0.268 mmol/L. Pru-
nasin is the major metabolite of amygdalin in vivo, and has very
high exposure in human serum. Interestingly, glycyrrhizin has
been considered as an efficacious therapeutic agent for COVID-19
with potential ACE2 binding activity30. In this study, we
confirmed that the KD value of glycyrrhizin was 4.39 mmol/L.
Forsythoside A and forsythoside I were the major components in
Forsythiae Fructus, their affinities to ACE2 were assayed as 15.8
and 18.7 mmol/L, respectively. Rhein was another component with
high exposure in human serum, which was also found having a
moderate affinity to ACE2 with KD value calculated as
33.3 mmol/L. Due to the high exposure concentration of rhein in
human body, physcion, aloe-emodin and emodin 8-O-b-D-gluco-
side, with structural similarity with rhein, were also analyzed by
SPR. The experimental results show that they could also exhibit
ACE2 binding activity, indicating ACE2 binding potentials of
rhubarb anthraquinone compounds. Furthermore, rutin and itsmponents in human plasma sample. (A) Data from UPLCeHRMS
positive ion mode. The peaks with red labels show that the constitu-
OVID-19 pharmacological components of traditional Chinese medicine
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+ MODELdeglycosylated compounds (quercetin) had also been proved to
show certain binding ability with ACE2. The sensorgrams of
another five components with affinities to ACE2 protein were
shown in Supporting Information Figs. S4AeS4E. According to
the general criteria31, the situation of Rmax value exceeding 2
times of the response of compounds should be considered as
nonspecific binding ligands. As shown in Table 1, the Rmax values
of all positive components were less than 25 RU, conforming to
the characteristic of specific binding. The c2 values were all less
than 10, indicating the accuracy of the fitting curves of each
compound. As SPR is the gold standard for detecting drugetarget
interactions, these results indicate that all the candidate active
components screened by the comprehensive 2D ACE2 bio-
chromatography system could directly bind to ACE2 recombinant
protein with ideal affinities, which reveals the efficiency of
screening target constituents from complex chemical samples by
this system. It is worth mentioning that, although 13 main con-
stituents of LHQW was screened [ephedrine (1), pseudoephedrine
(2), gallic acid (3), (R,S)-goitrin (7), salidroside (16), forsythoside
E (27), cryptochlorogenic acid (41), secoxyloganin (79), liquiritin
(102), forsythoside B (122), quercitrin (152), forsythin (171) and
emodin (227)] by SPR, none of these compounds exhibited ACE2
binding ability, except forsythoside B, a structural analogue ofFigure 5 2D contour plots of (A) Positive drug, MLN-4760, (B) enrich
potential active components obtained by the comprehensive 2D ACE2 co
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might indicate the high efficiency of using biochromatography as
analysis strategy from the perspective of human exposure in the
discovery of active compounds of TCM. Among these 13 con-
stituents, ephedrine (1), pseudoephedrine (2), (R,S)-goitrin (7),
salidroside (16), quercitrin (152) and forsythin (171) have higher
human exposure. Although they did not show ACE2 binding ac-
tivity, their higher in vivo exposure reveals that the pharmaco-
logical effects of LHQW might also be synergistically exerted
from other targets, indicating the characteristics of the TCM’s
multi-target effects.
3.7. Inhibition of ACE2 activity by ACE2 binding components
The effects of positive drug and all candidate components on the
activity of ACE2 were tested using the ACE2 Inhibitor Screening
Kit. Based on the SPR results, rhubarb anthraquinone compounds,
forsythiaside compounds, neochlorogenic acid and its isomers, as
well as prunasin and glycyrrhizin with high in vivo exposure levels
were selected. As shown in Fig. 7A, the selective ACE2 inhibitor
MLN-4760 has strong inhibitory effect with IC50 at 0.063 mmol/L.
The three forsythosides A, B and I screened out by bio-
chromatography and SPR analysis all have ACE2 inhibitoryed urine samples, (C) LHQW extracts and (D) standard compounds of
lumn/C18 column/TOFMS system.
OVID-19 pharmacological components of traditional Chinese medicine
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Figure 6 SPR sensorgrams and the fitting curves of equilibrium dissociation constant (KD) of (A) MLN-4760, (B) neochlorogenic acid, (C)
amygdalin, (D) prunasin, (E) forsythoside I, (F) rutin, (G) forsythoside A, (H) glycyrrhizin, and (I) rhein.
Table 1 Affinities of candidate active components targeting
ACE2 protein obtained by SPR analysis.
Compd. KD
(mmol/L)
Rmax (RU) c
2
Neochlorogenic acid (19) 7.880 6.894 1.260
Amygdalin (33) 0.221 6.856 0.462
Prunasin (37) 0.268 3.814 0.244
Forsythoside I (104) 18.700 19.020 1.910
Rutin (124) 82.400 12.770 1.290
Forsythoside B (125) 61.000 10.620 0.328
Forsythoside A (128) 15.800 21.490 5.280
Quercetin (190) 21.100 12.780 1.580
Emodin 8-O-b-D-glucoside (195) 21.270 16.930 3.190
Aloe-emodin (216) 6.020 16.120 7.720
Glycyrrhizin (222) 4.390 9.614 0.321
Rhein (226) 33.300 13.200 0.669
Physcion (230) 0.379 18.390 1.630
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+ MODELeffects and the molecular docking confirmed that they could bind
to the typical peptidase active sites. While two compounds, for-
sythin and forsythoside E, with similar structures but no affinities,
have no ACE2 inhibitory activities (Fig. 7B). Rhein and emodin 8-
O-b-D-glucoside showed good ACE2 inhibitory effects with IC50
at 18.33 and 22.50 mmol/L, respectively, while the other major
components in Rhei Radix et Rhizoma did not show significant
inhibitory effects (Fig. 7C). Moreover, as shown in Fig. 7D, three
chlorogenic acid isomers all reveal moderate ACE2 inhibitory
activities with IC50 at about 40 mmol/L, while the two components
prunasin and glycyrrhizin, with strong ACE2 binding affinities,
did not show significant peptidase inhibitory effects. They failed
to bind with any of the peptidase active site, which was confirmed
by molecular docking assays. It is worth mentioning that the
in vivo exposure concentration of rhein is relatively high, with
good activity, indicating that it might be the main active ingredient
of LHQW to exert ACE2 inhibition ability. Other active com-
pounds, such as prunasin and glycyrrhizin, had high in vivo
exposure concentrations but low inhibitory activity; while for-
sythosides A and I, or neochlorogenic acid and its isomers had
good in vitro activity, but low in vivo exposure, which might show
synergistic effects with rhein. This might also reflect the combined
synergistic effect of TCM.
3.8. Molecular docking assays
Docking simulation studies were carried out to investigate the
binding sites of six representative components. Previous studies
showed that the main interaction interface of ACE2 that binding
with the RBD region of S protein are Gln24 to Tyr83 and Gln325
to Arg39332,33. It is worth mentioning that the peptidyl dipeptidase
activity sites were widely distributed in various regions at the N-
terminal of ACE2 protein, including Trp271 to Arg273, His345 toPlease cite this article as: Chen Xiaofei et al., Identifying potential anti-C
Lianhuaqingwen capsule based on human exposure and ACE2 biochromato
j.apsb.2020.10.002Ala387, and His505 to Arg51434,35. The potential intersection
region of peptidase activity and S protein binding is around
His345 to Arg393. Thus, the compounds that block S protein
binding to ACE2 may not have strong catalytic activity to inhibit
ACE2 peptidase36. Recent reports showed that some potential
ACE2 inhibitors screened by computer simulations do not directly
bind to the interface between ACE2 and spike protein complex37,
indicating that these compounds were not suitable for inhibiting
SARS-CoV-2 infection. In this case, it may be worthy to conduct
further exploration to identify whether their specific binding site is
directly bound to the contact surface between ACE2 and spike
complex or ACE2 peptidase active sites, as this interaction might
determine the compound’s molecular mechanism in inhibitingOVID-19 pharmacological components of traditional Chinese medicine
graphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
Figure 7 The inhibitory effects of candidate components on ACE2 enzymatic activity. (A) positive drug MLN-4760, (B) candidate components
from Forsythiae Fructus, (C) Rhei Radix et Rhizoma, and (D) Lonicerae Japonicae Flos/Armeniacae Semen Amarum Tostum/Glycyrrhizae Radix
et Rhizoma.
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+ MODELSARS-CoV-2 infection21. As shown in Fig. 8AeF, six components
with strong affinities, prunasin, forsythoside I, glycyrrhizin, rhein,
forsythoside A and neochlorogenic acid, could all form suitable
steric complementarities with the binding interface of ACE2 with
SARS-CoV-2 spike protein. Prunasin, a major metabolite of
amygdalin in serum, its glucoside and alkinyl groups contribute to
the affinity of the key binding interface of ACE2 and S protein
(His34 to Asp38). Forsythosides A and I, a pair of isomers, all
have good affinities and inhibitory effects to ACE2 protein. The
docking results show that they could bind to the intersection re-
gion of peptidase activity and S protein binding (Asp350 to
Arg393), while forsythoside B with an additional pentose showed
lower affinity and docking score probably due to the steric hin-
drance. Glycyrrhizin also showed good affinity to ACE2 protein
but poor inhibitory effect. The docking result indicates glycyr-
rhizin could only bind to the region (Lys26 to Asp30) and not bind
to any of the peptidase region. Rhein showed the best ACE2
inhibitory effect, and was confirmed by the molecular docking that
the carboxyl could form hydrogen bond to Ala387, a key pepti-
dase active site. The similar situation was observed on emodin 8-
O-b-D-glucoside. However, aloe-emodin showed good affinity to
ACE2 protein but no inhibitory effect. The docking result reveals
it could bind to the sites of Glu35 and Gln76 with phenolic hy-
droxyl group, not peptidase sites (Supporting Information
Fig. S5). Neochlogrogenic acid and its isomers could form 4
hydrogen bonds to the intersection region of peptidase activity and
S protein binding (Ala348 to Arg393), indicating the potential
double inhibition of S protein binding and ACE2 enzyme activity.
4. Discussion
A TCM product usually contains from several dozens to a few
hundreds of prototype components, while each constituent might
change quantitatively with environmental factors or processing
conditions14,38. TCM component profiles in human and animals
become much complicated due to biotransformation by metabo-
lizing enzymes, which makes identification of in vivo TCMPlease cite this article as: Chen Xiaofei et al., Identifying potential anti-C
Lianhuaqingwen capsule based on human exposure and ACE2 biochromatog
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challenging.
A novel strategy for the discovery of ACE2 inhibitory active
components in LHQW that may play important roles in COVID-
19 pneumonia treatment was established in this study (Fig. 9). In
the first step, UPLCeHRMS was utilized to comprehensively
analyze and identify the chemical compositions of LHQW.
Resultant information was utilized for subsequent identification of
LHQW components exposed to human. In the second step, major
LHQW components in human urine were detected and structurally
characterized followed by their inhibitory effects on ACE2 using
2D biochromatography. In the last step, SPR and ACE2 inhibitory
activity assay were applied to confirm the pharmacodynamics of
active components from the screening, while computer docking
was used to elaborate on the possible sites of pharmacology ac-
tion. The most important element of this strategy was to combine
in human exposure study with 2D-biochromatography analysis,
which was proved to be efficient in revealing the active compo-
nents from LHQW that may exhibit inhibitory effects on ACE2 in
human.
In this study, a LHQW test solution sample was initially used
for setting up for UPLCeHRMS method as well as characterizing
structures of LHQW prototype components (Fig. 2) to support
identification of LHQW component in vivo. As shown in Table S1,
126 prototypes in the LHQW test solution were tentatively iden-
tified and 34 prototypes of them were fully confirmed by using
reference standards, which were significantly more than the total
prototype components found in LHQW in a previous study
although major components identified from the two studies are
similar17. Furthermore, the HRMS-based PATBS technique was
applied to detection of LHQW components in human urine and
plasma samples using a workflow previously developed for
studying ADME of TCM in vivo19. PATBS is an untargeted data-
mining tool capable of finding TCM components or other types of
xenobiotics in a test in vivo sample regardless of their molecular
weights, mass defects, isotope patterns and fragmentations since
these xenobiotics were not present in a corresponding controlOVID-19 pharmacological components of traditional Chinese medicine
raphy screening, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/
Figure 8 Molecular docking results of (A) prunasin, (B) forsythoside I, (C) glycyrrhizin, (D) rhein, (E) forsythoside A, and (F) neochlorogenic
acid.
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+ MODELsample such as a pre-dosing plasma and urine sample. As shown
in Fig. 3, PATBS not only removed large portions of endogenous
components and background noise to reveal minor LHQW com-
ponents (Fig. 3D and E), but also significantly cleaned full-scan
MS spectral data to make molecular ions of interest as dominant
ion species (Fig. 3F). Both metabolomics approach and PATBS
are untargeted data mining tools and their effectiveness of finding
xenobiotics is comparable. However, PATBS has two significant
advantages39. First, PATBS can be used in a combination with
targeted or semi-targeted data mining tools, such as extracted ion
chromatographic processing or mass defect filters, to increase
detection sensitivity and selectivity20. Second, PATBS is capable
of processing a single test sample by using a single control sam-
ple, while the metabolomics approach requires analysis two
groups of test and control samples and each of the group has three
or more samples. Results from this study demonstrate that HRMS
combined with PATBS is a superior data-mining tool for studying
ADME of a TCM product in human.Figure 9 The main process and results of the study on the
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after oral administration of a TCM product is considered as a very
important step to investigate molecular mechanisms of its phar-
maceutical effects in human. In this study, we detected and
characterize a total of 107 LHQW components (66 prototypes and
41 metabolites) in human plasma after oral administration of
therapeutic doses (Table S1). In addition, UPLCeHRMS profiles
of plasma samples provided semi-quantitative estimation on the
LHQW components in the human circulation (Fig. 4A and B).
Based on the information, more accurate quantification of circu-
lating components in human can be performed using LCeMS and
their reference standards. Furthermore, we found additional 21
LHQW prototype components that were absorbed and then un-
derwent rapid metabolic clearance or renal excretion. These
LHQW components were also exposed to human even without the
significant presence in the circulation. The approach significantly
reduced cost and time in studying pharmacological mechanism of
LHQW by avoiding testing over a large number of individualpotential active components of LHQW against COVID-19.
OVID-19 pharmacological components of traditional Chinese medicine
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+ MODELprototype components that were found in LHQW test solution, but
unlikely exposed to human.
The experimental results from this study show that many of the
main exposed constituents of LHQW in the human body have
good affinity with ACE2. However, our results show that not all
compounds with high affinities to ACE2 recombinant protein
presented significant enzymatic inhibitory effect, which was
owing to the difference of peptidase active sites and S protein
binding sites of ACE2 protein. Several components were screened
out with strong affinities to S protein binding sites, or binding to
the intersection region of peptidase activity and S protein binding
sites. This result might indicate an advantage of TCM with mul-
tiple drugs, as these multiple drug combination might show
superimposed effects and exert their effects together. In this case,
the clinical toxic side effects caused by single potent ACE2 in-
hibitor might be avoided. Previous studies have shown that
LHQW could significantly inhibit the replication of SARS-CoV-2
in cells, and the number of virus particles was significantly
reduced after LHQW treatment5. On the other side, cytokine storm
(or inflammatory storm) is an excessive immune response of the
body to external stimuli such as viruses and bacteria, which rep-
resents an important node in the development of COVID-19 from
mild to severe or critical status. LHQW could significantly inhibit
the gene overexpression of the inflammatory factors (for example,
TNF-a, IL-6, MCP-1, or IP-10), caused by SARS-CoV-2
infection40e43. It is worth mentioned that the current studies on
the combination of the main exposed components of LHQW in the
body and its possible interaction with ACE2 have been rarely
reported. This interesting result also illustrates that it is necessary
to conduct research on the efficacy of TCM from an in vivo
exposure perspective.5. Conclusions
In this study, human exposure to LHQW components after 8
repeated therapeutic doses were evaluated by determining
LHQW component profiles in human plasma and urine, which
were accomplished mainly by acquiring accurate MS and MS
datasets using UPLCeHRMS and processing the MS dataset
using PATBS for untargeted detection of LHQW components.
As a result, a total of 86 LHQW components in human were
tentatively identified based on spectral data interpretation or
marching, among which 22 constituents were confirmed using
reference standards. Furthermore, a novel ACE2 bio-
chromatographic stationary phase was synthesized to screen for
potential ACE2-target components in human urine sample and
LHQW extract. Based on the data obtained from human
exposure and comprehensive 2D ACE2 biochromatography
system, selected LHQW components were subjected to further
pharmacodynamic evaluation SPR and ACE2 inhibition assays.
Results show that 8 components, including neochlorogenic
acid, amygdalin, prunasin, forsythoside I, rutin, forsythoside A,
glycyrrhizin and rhein, exhibited binding affinities to ACE2
with KD values ranging from 0.221 to 82.40 mmol/L. The
ACE2 Inhibitor Screening Kit further verified the activity of
the selected constituents. Finally, rhein, forsythoside A, for-
sythoside I, neochlorogenic acid and its isomers showed ACE2
inhibitory effects. Together, these active LHQW components
circulating in human may play synergistic roles therapeutically
with reduced side effect. It is worth mentioning that these
constituents not only showed good affinity to ACE2 but alsoPlease cite this article as: Chen Xiaofei et al., Identifying potential anti-C
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complex, which was confirmed by computer-aided docking
results. To the best of our knowledge, this was the first report
of comprehensive study on human exposure to LHQW com-
ponents. More importantly, it was found that several LHQW
components exposed to human might play potential roles in
inhibiting SARS-CoV-2 by significantly affecting the binding
between ACE2 and S protein, which is an important route of
preventing virus infection. This study provided direct chemical
and biochemical evidences associated with molecular mecha-
nisms of clinical use of LHQW for prevention and treatment of
COVID-19. In addition, this study demonstrates the utility of
human exposure-based approach to identifying pharmacologi-
cally active components in a herbal medicine product with
approved therapeutic effects.
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